Cargando…

Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies

The mechanism of RNA interference (RNAi) could represent a breakthrough in the therapy of all diseases that arise from a gene defect or require the inhibition of a specific gene expression. In particular, small interfering RNA (siRNA) offers an attractive opportunity to achieve a new milestone in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabel, Michael, Knauss, Annkathrin, Fischer, Dagmar, Neurath, Markus F., Weigmann, Benno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692731/
https://www.ncbi.nlm.nih.gov/pubmed/36430411
http://dx.doi.org/10.3390/ijms232213929
_version_ 1784837341962043392
author Gabel, Michael
Knauss, Annkathrin
Fischer, Dagmar
Neurath, Markus F.
Weigmann, Benno
author_facet Gabel, Michael
Knauss, Annkathrin
Fischer, Dagmar
Neurath, Markus F.
Weigmann, Benno
author_sort Gabel, Michael
collection PubMed
description The mechanism of RNA interference (RNAi) could represent a breakthrough in the therapy of all diseases that arise from a gene defect or require the inhibition of a specific gene expression. In particular, small interfering RNA (siRNA) offers an attractive opportunity to achieve a new milestone in the therapy of human diseases. The limitations of siRNA, such as poor stability, inefficient cell uptake, and undesired immune activation, as well as the inability to specifically reach the target tissue in the body, can be overcome by further developments in the field of nanoparticulate drug delivery. Therefore, types of surface modified siRNA nanoparticles are presented and illustrate how a more efficient and safer distribution of siRNA at the target site is possible by modifying the surface properties of nanoparticles with antibodies. However, the development of such efficient and safe delivery strategies is currently still a major challenge. In consideration of that, this review article aims to demonstrate the function and targeted delivery of siRNA nanoparticles, focusing on the surface modification via antibodies, various lipid- and polymer-components, and the therapeutic effects of these delivery systems.
format Online
Article
Text
id pubmed-9692731
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96927312022-11-26 Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies Gabel, Michael Knauss, Annkathrin Fischer, Dagmar Neurath, Markus F. Weigmann, Benno Int J Mol Sci Review The mechanism of RNA interference (RNAi) could represent a breakthrough in the therapy of all diseases that arise from a gene defect or require the inhibition of a specific gene expression. In particular, small interfering RNA (siRNA) offers an attractive opportunity to achieve a new milestone in the therapy of human diseases. The limitations of siRNA, such as poor stability, inefficient cell uptake, and undesired immune activation, as well as the inability to specifically reach the target tissue in the body, can be overcome by further developments in the field of nanoparticulate drug delivery. Therefore, types of surface modified siRNA nanoparticles are presented and illustrate how a more efficient and safer distribution of siRNA at the target site is possible by modifying the surface properties of nanoparticles with antibodies. However, the development of such efficient and safe delivery strategies is currently still a major challenge. In consideration of that, this review article aims to demonstrate the function and targeted delivery of siRNA nanoparticles, focusing on the surface modification via antibodies, various lipid- and polymer-components, and the therapeutic effects of these delivery systems. MDPI 2022-11-11 /pmc/articles/PMC9692731/ /pubmed/36430411 http://dx.doi.org/10.3390/ijms232213929 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gabel, Michael
Knauss, Annkathrin
Fischer, Dagmar
Neurath, Markus F.
Weigmann, Benno
Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies
title Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies
title_full Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies
title_fullStr Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies
title_full_unstemmed Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies
title_short Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies
title_sort surface design options in polymer- and lipid-based sirna nanoparticles using antibodies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692731/
https://www.ncbi.nlm.nih.gov/pubmed/36430411
http://dx.doi.org/10.3390/ijms232213929
work_keys_str_mv AT gabelmichael surfacedesignoptionsinpolymerandlipidbasedsirnananoparticlesusingantibodies
AT knaussannkathrin surfacedesignoptionsinpolymerandlipidbasedsirnananoparticlesusingantibodies
AT fischerdagmar surfacedesignoptionsinpolymerandlipidbasedsirnananoparticlesusingantibodies
AT neurathmarkusf surfacedesignoptionsinpolymerandlipidbasedsirnananoparticlesusingantibodies
AT weigmannbenno surfacedesignoptionsinpolymerandlipidbasedsirnananoparticlesusingantibodies